JP2017538446A5 - - Google Patents

Download PDF

Info

Publication number
JP2017538446A5
JP2017538446A5 JP2017547931A JP2017547931A JP2017538446A5 JP 2017538446 A5 JP2017538446 A5 JP 2017538446A5 JP 2017547931 A JP2017547931 A JP 2017547931A JP 2017547931 A JP2017547931 A JP 2017547931A JP 2017538446 A5 JP2017538446 A5 JP 2017538446A5
Authority
JP
Japan
Prior art keywords
recombinant protein
perfusion
mammalian host
bioreactor
culture medium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017547931A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017538446A (ja
JP6698681B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/063271 external-priority patent/WO2016089919A1/en
Publication of JP2017538446A publication Critical patent/JP2017538446A/ja
Publication of JP2017538446A5 publication Critical patent/JP2017538446A5/ja
Application granted granted Critical
Publication of JP6698681B2 publication Critical patent/JP6698681B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017547931A 2014-12-01 2015-12-01 糖タンパク質のグリカン含量のレベルを操作するためのプロセス Active JP6698681B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462085759P 2014-12-01 2014-12-01
US62/085,759 2014-12-01
PCT/US2015/063271 WO2016089919A1 (en) 2014-12-01 2015-12-01 Process for manipulating the level of glycan content of a glycoprotein

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020080270A Division JP7066775B2 (ja) 2014-12-01 2020-04-30 糖タンパク質のグリカン含量のレベルを操作するためのプロセス

Publications (3)

Publication Number Publication Date
JP2017538446A JP2017538446A (ja) 2017-12-28
JP2017538446A5 true JP2017538446A5 (enExample) 2019-01-17
JP6698681B2 JP6698681B2 (ja) 2020-05-27

Family

ID=55024253

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2017547931A Active JP6698681B2 (ja) 2014-12-01 2015-12-01 糖タンパク質のグリカン含量のレベルを操作するためのプロセス
JP2020080270A Active JP7066775B2 (ja) 2014-12-01 2020-04-30 糖タンパク質のグリカン含量のレベルを操作するためのプロセス
JP2022072126A Pending JP2022101669A (ja) 2014-12-01 2022-04-26 糖タンパク質のグリカン含量のレベルを操作するためのプロセス
JP2024063188A Pending JP2024095777A (ja) 2014-12-01 2024-04-10 糖タンパク質のグリカン含量のレベルを操作するためのプロセス

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2020080270A Active JP7066775B2 (ja) 2014-12-01 2020-04-30 糖タンパク質のグリカン含量のレベルを操作するためのプロセス
JP2022072126A Pending JP2022101669A (ja) 2014-12-01 2022-04-26 糖タンパク質のグリカン含量のレベルを操作するためのプロセス
JP2024063188A Pending JP2024095777A (ja) 2014-12-01 2024-04-10 糖タンパク質のグリカン含量のレベルを操作するためのプロセス

Country Status (22)

Country Link
US (5) US10167492B2 (enExample)
EP (2) EP3680344A1 (enExample)
JP (4) JP6698681B2 (enExample)
KR (1) KR102623965B1 (enExample)
CN (1) CN107109455B (enExample)
AU (5) AU2015355087C1 (enExample)
CA (1) CA2969225C (enExample)
CL (1) CL2017001369A1 (enExample)
CY (1) CY1123247T1 (enExample)
DK (1) DK3227454T3 (enExample)
EA (2) EA036178B1 (enExample)
ES (1) ES2784503T3 (enExample)
HU (1) HUE049201T2 (enExample)
IL (2) IL276165B (enExample)
LT (1) LT3227454T (enExample)
MX (1) MX385409B (enExample)
PL (1) PL3227454T3 (enExample)
PT (1) PT3227454T (enExample)
SG (2) SG10202002458PA (enExample)
SI (1) SI3227454T1 (enExample)
WO (1) WO2016089919A1 (enExample)
ZA (2) ZA201703729B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3227454T1 (sl) 2014-12-01 2020-06-30 Amgen Inc. Postopek za manipuliranje ravni vsebnosti glikana glikoproteina
WO2017117218A1 (en) 2015-12-30 2017-07-06 Momenta Pharmaceuticals, Inc. Methods related to biologics
JP7672196B2 (ja) * 2017-03-14 2025-05-07 アムジエン・インコーポレーテツド 細胞培養において産生される抗体の総非フコシル化グリコフォームの調節
US11702628B2 (en) * 2017-03-31 2023-07-18 Boehringer Ingelheim International Gmbh Perfusion medium for culturing mammalian cells and reducing cell bleed in a perfusion cell culture
WO2019105444A1 (zh) * 2017-11-30 2019-06-06 正大天晴药业集团南京顺欣制药有限公司 蛋白质的生产方法
KR20200135781A (ko) * 2018-03-26 2020-12-03 암젠 인크 세포 배양에서 생산된 항체의 총 비푸코실화 당형태
CA3099917A1 (en) * 2018-05-24 2019-11-28 Ares Trading S.A. Method for controlling the afucosylation level of a glycoprotein composition
MX2020013036A (es) 2018-06-05 2021-02-26 Amgen Inc Modulacion de la fagocitosis celular dependiente de anticuerpos.
CA3110530A1 (en) 2018-09-11 2020-03-19 Amgen Inc. Methods of modulating antibody-dependent cell-mediated cytotoxicity
HU231514B1 (hu) * 2018-11-07 2024-07-28 Richter Gedeon Nyrt. Sejttenyészetben előállított rekombináns glikoprotein glikozilációs mintázatának megváltoztatására szolgáló módszer
MA54248A (fr) 2018-11-13 2021-09-22 Janssen Biotech Inc Régulation de métaux traces pendant la production d'anticorps anti-cd38
CA3125443A1 (en) * 2018-12-31 2020-07-09 Momenta Pharmaceuticals, Inc. Methods of producing ustekinumab
CA3127228A1 (en) * 2019-01-30 2020-08-06 Amgen Inc. Aflibercept attributes and methods of characterizing and modifying thereof
WO2020227726A1 (en) 2019-05-06 2020-11-12 Amgen Inc. Modulating antibody effector functions
JP2020188737A (ja) * 2019-05-23 2020-11-26 東ソー株式会社 抗体依存性細胞傷害活性が向上した抗体の製造方法
MX2022003461A (es) 2019-09-26 2022-04-19 Amgen Inc Metodos de produccion de composiciones de anticuerpos.
JP2023503849A (ja) 2019-11-15 2023-02-01 ロンザ リミテッド 接種物を生産するためのプロセスおよびシステム
US20230287335A1 (en) * 2020-07-30 2023-09-14 Amgen Inc. Cell culture media and methods of making and using the same
JP2023537760A (ja) * 2020-08-14 2023-09-05 ブリストル-マイヤーズ スクイブ カンパニー タンパク質の製造工程
MX2023004364A (es) 2020-10-15 2023-05-03 Amgen Inc Glucanos no emparejados relativos en metodos de produccion de anticuerpos.
AU2022289365A1 (en) 2021-06-07 2023-12-14 Amgen Inc. Using fucosidase to control afucosylation level of glycosylated proteins
AU2023223660A1 (en) * 2022-02-25 2024-08-01 Kashiv Biosciences, Llc A process for improving polypeptide expression in mammalian cell culture
AU2024256160A1 (en) 2023-04-20 2025-10-02 Amgen Inc. Methods of determining relative unpaired glycan content
CN121712803A (zh) * 2023-08-16 2026-03-20 葛兰素史密斯克莱知识产权有限公司 控制抗体糖基化谱的方法

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
AU588819B2 (en) 1984-10-29 1989-09-28 Immunex Corporation Cloning of human granulocyte-macrophage colony stimulating factor gene
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
US6048728A (en) 1988-09-23 2000-04-11 Chiron Corporation Cell culture medium for enhanced cell growth, culture longevity, and product expression
AU643427B2 (en) 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
DE10399023I2 (de) 1989-09-12 2006-11-23 Ahp Mfg B V TFN-bindende Proteine
US6204363B1 (en) 1989-10-16 2001-03-20 Amgen Inc. Stem cell factor
US5149792A (en) 1989-12-19 1992-09-22 Amgen Inc. Platelet-derived growth factor B chain analogs
US5272064A (en) 1989-12-19 1993-12-21 Amgen Inc. DNA molecules encoding platelet-derived growth factor B chain analogs and method for expression thereof
US5350683A (en) 1990-06-05 1994-09-27 Immunex Corporation DNA encoding type II interleukin-1 receptors
AU651596B2 (en) 1990-06-05 1994-07-28 Immunex Corporation Type II interleukin-1 receptors
US5096816A (en) 1990-06-05 1992-03-17 Cetus Corporation In vitro management of ammonia's effect on glycosylation of cell products through pH control
US6284471B1 (en) * 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
WO1994010308A1 (en) 1992-10-23 1994-05-11 Immunex Corporation Methods of preparing soluble, oligomeric proteins
US5554512A (en) 1993-05-24 1996-09-10 Immunex Corporation Ligands for flt3 receptors
US5981713A (en) 1994-10-13 1999-11-09 Applied Research Systems Ars Holding N.V. Antibodies to intereleukin-1 antagonists
US5721121A (en) 1995-06-06 1998-02-24 Genentech, Inc. Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein
ES2253753T3 (es) 1995-06-29 2006-06-01 Immunex Corporation Citocina que induce apoptosis.
US6613544B1 (en) 1995-12-22 2003-09-02 Amgen Inc. Osteoprotegerin
US6096728A (en) 1996-02-09 2000-08-01 Amgen Inc. Composition and method for treating inflammatory diseases
US6271349B1 (en) 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US6337072B1 (en) 1998-04-03 2002-01-08 Hyseq, Inc. Interleukin-1 receptor antagonist and recombinant production thereof
US6528286B1 (en) 1998-05-29 2003-03-04 Genentech, Inc. Mammalian cell culture process for producing glycoproteins
JP2001120262A (ja) * 1999-10-26 2001-05-08 Welfide Corp 生理活性物質の産生増強方法
WO2001036637A1 (en) 1999-11-17 2001-05-25 Immunex Corporation Receptor activator of nf-kappa b
US6544424B1 (en) 1999-12-03 2003-04-08 Refined Technology Company Fluid filtration system
CN101255192A (zh) 2000-05-26 2008-09-03 布里斯托尔-迈尔斯斯奎布公司 可溶性ctla4突变体分子及其应用
AU2003236018A1 (en) 2002-04-09 2003-10-20 Kyowa Hakko Kirin Co., Ltd. METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcGamma RECEPTOR IIIa
DE10312765A1 (de) 2003-03-21 2004-09-30 Bayer Technology Services Gmbh Vorrichtung und Verfahren zur Sterilisation flüssiger Medien mittels UV-Bestrahlung und Kurzzeiterhitzung
TWI384069B (zh) 2004-08-27 2013-02-01 Pfizer Ireland Pharmaceuticals 多胜肽之製法
TWI364458B (en) * 2004-08-27 2012-05-21 Wyeth Res Ireland Ltd Production of tnfr-lg
US8053238B2 (en) 2005-10-31 2011-11-08 Unhwa Corporation Isolated population of plant single cells and method of preparing the same
US20070231895A1 (en) 2005-11-02 2007-10-04 Lee Gene W Methods for adapting mammalian cells
US7972810B2 (en) 2005-12-08 2011-07-05 Amgen Inc. Production of glycoproteins using manganese
WO2007081031A1 (ja) * 2006-01-16 2007-07-19 Hokkaido University 糖転移酵素阻害剤
US20100166741A1 (en) * 2006-07-13 2010-07-01 Genentech , Inc. Altered br-3 binding polypeptides
DK3255141T3 (da) 2006-07-13 2022-01-31 Wyeth Llc Fremstilling af antistoffer med forbedret glycosyleringsmønster
FR2904558B1 (fr) * 2006-08-01 2008-10-17 Lab Francais Du Fractionnement "composition de facteur vii recombinant ou transgenique, presentant majoritairement des formes glycanniques biantennees, bisialylees et non fucosylees"
EP2395077A1 (en) 2006-11-03 2011-12-14 Wyeth LLC Glycolysis-inhibiting substances in cell culture
JP5586235B2 (ja) 2007-03-02 2014-09-10 ワイス・エルエルシー ポリペプチドの産生のための細胞培養における銅およびグルタミン酸塩の使用
CA2682472A1 (en) * 2007-03-30 2008-10-09 Centocor Ortho Biotech Inc. High expression clones of mammalian cells with fluorescent protein a or g
CA2682738A1 (en) 2007-04-16 2008-10-23 Momenta Pharmaceuticals, Inc. Defined glycoprotein products and related methods
WO2008154014A2 (en) 2007-06-11 2008-12-18 Amgen Inc. A method for culturing mammalian cells to improve recombinant protein production
DE602008006410D1 (de) 2007-06-15 2011-06-01 Amgen Inc Verfahren zur behandlung von zellkulturmedien für die verwendung in einem bioreaktor
EP2438185A4 (en) 2009-06-05 2016-10-05 Momenta Pharmaceuticals Inc METHODS FOR MODULATING FUCOSYLATION OF GLYCOPROTEINS
KR20140032944A (ko) 2010-10-20 2014-03-17 모르포테크, 인크. 항폴레이트 수용체 알파 항체 당형태
JP2014506482A (ja) 2011-02-23 2014-03-17 アムジエン・インコーポレーテツド Uvc露光のための細胞培養培地およびそれに関連した方法
WO2012120500A2 (en) * 2011-03-06 2012-09-13 Merck Serono S.A. Low fucose cell lines and uses thereof
WO2012145682A1 (en) 2011-04-21 2012-10-26 Amgen Inc. A method for culturing mammalian cells to improve recombinant protein production
EP2702077A2 (en) 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
CA2838695C (en) 2011-07-01 2017-02-14 Amgen Inc. Mammalian cell culture
AR087433A1 (es) * 2011-08-08 2014-03-26 Merck Sharp & Dohme Analogos de insulina n-glicosilados
WO2013040444A1 (en) 2011-09-16 2013-03-21 Amgen Inc. Pre-programmed non-feedback controlled continuous feeding of cell cultures
SG11201401739YA (en) 2011-10-26 2014-05-29 Amgen Inc Methods of reducing or eliminating protein modification and degradation arising from exposure to uv light
CN104487570A (zh) * 2012-01-20 2015-04-01 新加坡科技研究局 Cho-gmt重组蛋白的表达
EP2809773B1 (en) 2012-01-30 2020-09-02 Dr. Reddy's Laboratories Limited Process of modulating man5 and/or afucosylation content of glycoprotein composition
WO2013114164A1 (en) 2012-01-30 2013-08-08 Dr. Reddy's Laboratories Limited Method for obtaining glycoprotein composition with increased afucosylation content
WO2013138159A1 (en) 2012-03-15 2013-09-19 Amgen Inc. Methods of determining exposure to uv light
US10481164B2 (en) 2012-03-26 2019-11-19 Amgen Inc. Method for using light scattering in real time to directly monitor and control impurity removal in purification processes
EP2905290B1 (en) * 2012-10-05 2019-12-04 Kyowa Kirin Co., Ltd. Heterodimeric protein composition
US8956830B2 (en) 2013-03-14 2015-02-17 Momenta Pharmaceuticals, Inc. Methods of cell culture
US9677105B2 (en) 2013-03-14 2017-06-13 Momenta Pharmaceuticals, Inc. Methods of cell culture
SG11201600067YA (en) 2013-07-23 2016-02-26 Biocon Ltd Methods for controlling fucosylation levels in proteins
RU2712562C2 (ru) * 2014-02-27 2020-01-29 Ф.Хоффманн-Ля Рош Аг Модулирование клеточного роста и гликозилирования при производстве рекомбинантных гликопротеинов
WO2016068799A1 (en) * 2014-10-27 2016-05-06 Agency For Science, Technology And Research Methods of recombinant protein expression in a cell comprising reduced udp-galactose transporter activity
SI3227454T1 (sl) 2014-12-01 2020-06-30 Amgen Inc. Postopek za manipuliranje ravni vsebnosti glikana glikoproteina

Similar Documents

Publication Publication Date Title
JP2017538446A5 (enExample)
IL310968B1 (en) Mammalian cell culture
CN103320390B (zh) 一种大规模哺乳动物工程细胞培养方法
RU2009139054A (ru) ПРИМЕНЕНИЕ НИЗКОЙ ТЕМПЕРАТУРЫ И/ИЛИ НИЗКОГО pН В КУЛЬТУРЕ КЛЕТОК
JP2017501749A5 (enExample)
JP2010110331A5 (enExample)
CN108884428A (zh) 对连续流动搅拌釜反应器细胞培养系统的连接灌注
JP2012519485A5 (enExample)
TW202328427A (zh) 超高密度細胞儲存方法
CN103773741A (zh) 笼式通气搅拌生物反应器制备流感疫苗的方法
CN102382794B (zh) 一种哺乳动物细胞的灌流培养方法
KR20200128108A (ko) 생물 대분자 업스트림 단계별 차단의 생산 방법, 생산 모듈 및 생산에서의 응용
JP2019514411A5 (enExample)
WO2021008571A1 (zh) 高密度连续接种的细胞培养方法及其应用
CN106222129A (zh) 一种提高抗体纯度的细胞培养基和培养方法
CN107299078A (zh) 一株适应全悬浮培养的猫肾细胞系f‑81 s及其应用
CN104206173B (zh) 一种利用野生猴头菇袋料栽培的方法
EA202092904A1 (ru) Способы получения рекомбинантных белков
CN109628407A (zh) 高密度长期培养表达抗vegf人源化单克隆抗体重组cho细胞的方法
CN104982321B (zh) 一种马铃薯脱毒苗叠式培养盘及其使用方法
CN109134645A (zh) 一种细胞浓缩补料培养工艺
WO2018018613A1 (zh) 一种提高抗体纯度的细胞培养基和培养方法
CN101838661B (zh) 一种高稳定性藻蓝蛋白类融合荧光蛋白质的制备方法
CN109988803A (zh) 一种高效生产重组人血清白蛋白的发酵方法
CN102776260B (zh) 一种高效表达重组人凝血八因子的方法